1Arroyo V,Gines P,Gerbes AL,et al.Definition and diagnostic ritcriaof re fr-actory ascitcs and hepatorcnal syndrome in cirrhosis.International As cite-sClub[J].Hepatology,1996,23(1):164.
5Solanki P,Chawla A.Benificial effect of terlipression in hepatorenalsy ndrome:a prospective,randomized placebo controlled clinicaltrial[J].Gas troentrol Hepatol,2003,34(8):152-156.
6Ortega R,Cines P,Uriz J,et al.Terlipressin therapy with and without albumin for patients with hepatorenal syndrome:results of a prospective,nonrandomized study[J].Hepatology,2002,36(4 Pt 1):941-948.
7Alessandria C,Ottobrelli A,Debernardi-Venon W,et al.Noradrenalin vs t erlipressin in patients with hepatorenal syndrome:a prospective,randomi zed,unblinded,pilot study[J].Hcpatology,2007,47(4):499-505.
8Esrailian E,Pantangco ER,Kyulo NL,et al.Octreotide/Midodrine therapy si gnificantly improves renal function and 30-day survival in patients with type 1hepatorenal syndrome[J].Digestive Dis-eases And Sciences,2007,52(3):742-748.
9Arroyo V,Ginesp,gerbes AL,et al.Definition and diagnostic criteria of r efractory ascites and hepatorenal syndrome in cirrhosis[J].Hepatology,1996,23:1-176.
10BrensingKA,TextorJ,StrunkH,et al.Transjugular intrahepatic portosystem icstent-shunt for hepatorenal sydrome[J].Lancet,1997,349(9053):697-698.
2Arroyo V, Gines P, Gerbes AL, et al. Deflnition and diagnostic criteria of refractory ascites and hepatorenal syndrorne in cirrhosis[J]. Hepatology, 1996,23:164.
